Welcome to the 2nd Cell Therapy for Autoimmune Disease Summit
Following the latest data revealing the promise of cell therapies for lupus, all eyes are on how to pave the way to develop the first curative treatments for autoimmune patients
The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year's explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This is your unmissable opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication.
Join 30+ trailblazers including Cartesian Therapeutics, Bristol Myers Squibb, the University of Pennsylvania, ImmPACT Bio and more as they unveil their latest clinical updates, next-generation candidates, novel antigen targets, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease.
With a brand new 2 tracked agenda, hear in-depth presentations across preclinical development versus clinical strategy to strategically gain the insight your team needs to boost your candidates among industry pioneers. This year will be the biggest edition of this meeting yet as this community expands to grasp every opportunity available.
URL:
Brochure: https://go.evvnt.com/2619398-3?pid=263
Prices:
Conference Only- Academic Pricing: USD 2599.00,
Conference + 1 Workshop- Academic Pricing: USD 3098.00,
Conference + 2 Workshops - Academic Pricing: USD 3597.00
Conference Only- Solution Provider Pricing: USD 3699.00,
Conference + 1 Workshop- Solution Provider Pricing: USD 4398.00,
Conference + 2 Workshops- Solution Provider Pricing: USD 5097.00,
Conference Only- Drug Developer Pricing: USD 2999.00,
Conference + 1 Workshop- Drug Developer Pricing: USD 3598.00,
Conference + 2 Workshops- Drug Developer Pricing: USD 4197.00
Speakers: Chris Jewell, Chief Scientific Officer, Cartesian Therapeutics, Chris Rudulier, Associate Director - Autoimmunity, Intellia Therapeutics, David Porter,Director - Cell Therapy and Transplant, Penn Medicine/ University of Pennsylvania, Ellen Cahir-McFarland, Chief Scientific Officer, Abata Therapeutics, Fred Aslan, President and Chief Executive Officer, Artiva Biotherapeutics, Inc, Greg Deener, Chief Executive Officer, iCell Gene Therapeutics, Haig Aghajanian, Co-Founder, Vice President and Head of Research, Capstan Therapeutics, Isin Dalkilic, Senior Director, Drug Discovery, Orna Therapeutics, Jason Damiano, Chief Scientific Officer, Appia Bio, Jeffrey Jones, Chief Medical Officer, Cullinan Therapeutics, Inc, Jennifer Bush, Chief Operating Officer, Artiva Biotherapeutics, Inc, Laurence Morel, Professor and Chair, UT Health San Antonio, Marc Martinez Llordella, Co-founder and Vice President - Biology, Quell Therapeutics, Marko Radic, Ph.D. Associate Professor, The University of Tennessee Health Science Center, Marlene Carrasco, Global Clinical Head Immunology Cell Therapy, AstraZeneca, Matthew Collinson-Pautz, Director - Preclinical and Translational Research, Indapta Therapeutics, Maximilian Konig, Director Cellular Therapy Program Autoimmunity, John Hopkins University School of Medicine, Metin Kurtoglu, CTO, Cartesian Therapeutics, Mike Dybbs, Partner, Samsara BioCapital, Paolo Casali, University of Texas Ashbel Smith Distinguished Professor, UT Health San Antonio, Phil Johnson, Chief Scientific Officer, Interius Bio, Rachel Hourigan, Research Analyst Lead, Beacon, Rahul Patel, Independent Subject Matter Expert, Richard Ransohoff, Venture Partner, Third Rock Ventures LLC, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Shivani Srivastava, Vice President, Global Program Lead, Cell Therapy Organization, Bristol Myers Squibb, Stefanie Mandl, CSO, Indapta Therapeutics, Stephen Waggoner, Professor, Cincinatti Children's Medical Center, Susanne Diehl, Global Program Head Immunology, Novartis, Timothy Campbell, Founder and VP of Biology, Bristol Myers Squibb, Tom Wickham, Chief Scientific Officer, GentiBio, Tony Arulanandam, CEO and Founder, Synaptimmune Therapeutics, Yongke Zhang, SCO, IASO BioTherapeutics
Following the latest data revealing the promise of cell therapies for lupus, all eyes are on how to pave the way to develop the first curative treatments for autoimmune patients
The 2nd Cell Therapy for Autoimmune Disease Summit returns to Philadelphia bigger and better after last year's explosive debut as the only meeting covering every aspect of bringing cell therapies to the autoimmune space. This is your unmissable opportunity to learn the A-Zs of accelerating your candidates to be the first in the market and finally bring the cure for an autoimmune indication.
Join 30+ trailblazers including Cartesian Therapeutics, Bristol Myers Squibb, the University of Pennsylvania, ImmPACT Bio and more as they unveil their latest clinical updates, next-generation candidates, novel antigen targets, and translational biomarkers to turbocharge the development of cell therapies for autoimmune disease.
With a brand new 2 tracked agenda, hear in-depth presentations across preclinical development versus clinical strategy to strategically gain the insight your team needs to boost your candidates among industry pioneers. This year will be the biggest edition of this meeting yet as this community expands to grasp every opportunity available.
URL:
Brochure: https://go.evvnt.com/2619398-3?pid=263
Prices:
Conference Only- Academic Pricing: USD 2599.00,
Conference + 1 Workshop- Academic Pricing: USD 3098.00,
Conference + 2 Workshops - Academic Pricing: USD 3597.00
Conference Only- Solution Provider Pricing: USD 3699.00,
Conference + 1 Workshop- Solution Provider Pricing: USD 4398.00,
Conference + 2 Workshops- Solution Provider Pricing: USD 5097.00,
Conference Only- Drug Developer Pricing: USD 2999.00,
Conference + 1 Workshop- Drug Developer Pricing: USD 3598.00,
Conference + 2 Workshops- Drug Developer Pricing: USD 4197.00
Speakers: Chris Jewell, Chief Scientific Officer, Cartesian Therapeutics, Chris Rudulier, Associate Director - Autoimmunity, Intellia Therapeutics, David Porter,Director - Cell Therapy and Transplant, Penn Medicine/ University of Pennsylvania, Ellen Cahir-McFarland, Chief Scientific Officer, Abata Therapeutics, Fred Aslan, President and Chief Executive Officer, Artiva Biotherapeutics, Inc, Greg Deener, Chief Executive Officer, iCell Gene Therapeutics, Haig Aghajanian, Co-Founder, Vice President and Head of Research, Capstan Therapeutics, Isin Dalkilic, Senior Director, Drug Discovery, Orna Therapeutics, Jason Damiano, Chief Scientific Officer, Appia Bio, Jeffrey Jones, Chief Medical Officer, Cullinan Therapeutics, Inc, Jennifer Bush, Chief Operating Officer, Artiva Biotherapeutics, Inc, Laurence Morel, Professor and Chair, UT Health San Antonio, Marc Martinez Llordella, Co-founder and Vice President - Biology, Quell Therapeutics, Marko Radic, Ph.D. Associate Professor, The University of Tennessee Health Science Center, Marlene Carrasco, Global Clinical Head Immunology Cell Therapy, AstraZeneca, Matthew Collinson-Pautz, Director - Preclinical and Translational Research, Indapta Therapeutics, Maximilian Konig, Director Cellular Therapy Program Autoimmunity, John Hopkins University School of Medicine, Metin Kurtoglu, CTO, Cartesian Therapeutics, Mike Dybbs, Partner, Samsara BioCapital, Paolo Casali, University of Texas Ashbel Smith Distinguished Professor, UT Health San Antonio, Phil Johnson, Chief Scientific Officer, Interius Bio, Rachel Hourigan, Research Analyst Lead, Beacon, Rahul Patel, Independent Subject Matter Expert, Richard Ransohoff, Venture Partner, Third Rock Ventures LLC, Samik Basu, Chief Scientific Officer, Cabaletta Bio, Shivani Srivastava, Vice President, Global Program Lead, Cell Therapy Organization, Bristol Myers Squibb, Stefanie Mandl, CSO, Indapta Therapeutics, Stephen Waggoner, Professor, Cincinatti Children's Medical Center, Susanne Diehl, Global Program Head Immunology, Novartis, Timothy Campbell, Founder and VP of Biology, Bristol Myers Squibb, Tom Wickham, Chief Scientific Officer, GentiBio, Tony Arulanandam, CEO and Founder, Synaptimmune Therapeutics, Yongke Zhang, SCO, IASO BioTherapeutics
